Evaluation of the awareness, control and cost-effectiveness of hypertension treatment in a Brazilian city: Populational study

Journal of Hypertension

Volumn 27, Issue 9, 2009, Pages 1900-1907

  Moreira, Gisela C ^a   Cipullo, José P ^a   Vilela Martin, José F ^a   Ciorlia, Luiz A S ^a   Godoy, Maria R P ^a   Cesarino, Claudia B ^a   Cordeiro, José A ^a   Lupino, Plínio L ^a   Ciorlia, Gustavo ^a   Burdmann, Emmanuel A ^a  

^a Instituto de Urologia e Nefrologia   (Brazil)

Author keywords

Awareness; Control; Cost effectiveness; Hypertension; Treatment

Indexed keywords

ANGIOTENSIN 1 RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; METHYLDOPA;

ADULT; AGE DISTRIBUTION; AGED; ALPHA ADRENERGIC RECEPTOR BLOCKING; ANTIHYPERTENSIVE THERAPY; ARTICLE; AWARENESS; BLOOD PRESSURE REGULATION; BODY MASS; BRAZIL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; CROSS-SECTIONAL STUDY; DISEASE CONTROL; EDUCATION; EVALUATION; FEMALE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MORBIDITY; MORTALITY; POPULATION RESEARCH; PREVALENCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SEX DIFFERENCE; SOCIAL CLASS; SOCIOECONOMICS; STATISTICAL SIGNIFICANCE;

EID: 73249121438     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/HJH.0b013e32832dd10f     Document Type: Article

References (43)

1. Clausen J, Jensen G. Blood pressura and mortality: an epidemiological survey with 10 years follow-up. J Hum Hypertens 1992; 6:53-59.
2. lsraili ZH, Hernandez-Hernandez R, Valasco M. The future of antihypertensive treatment Am J Ther 2007; 14:121-134.
3. Lindholm LH. The problem of uncontrolled hypertension. J Hum Hypertens 2002; 16 (Suppl 3):S3-S8.
4. Williams B. The year in hypertension. J Am Coll Cardiol 2006; 48:1698-1711.
5. Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden of hypertension: analysis of worldwide data. Lancet 2005; 365:217-223. (Pubitemid 40138015)
6. Wang TJ, Vasan RS. Epidemiology of uncontrolled hypertension in the United States. Circulation 2005; 112:1651-1662. (Pubitemid 41324528)
7. Ong KL, Cheung BMY, Man YB, Lau CP, Lam KSL Prevalence, awareness, treatment, and control of hypertension among United States adults 1999-2004. Hypertension 2007; 49:69-75.
8. Chobanian AV, Bakris GI, Black HR, Cushman WC, Green LA, tzzo JL Jr, et al. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. The JNC 7 Report JAMA 2003; 289:2560-2572. (Pubitemid 37430158)
9. Sociedade Brasileira de Cardiologia - SBC, Sociedade Brasileira de Hipertensã - SBH, Sociedade Brasileira de Nefrologia - SBN.V Brazilian guidelines for arterial hypertension 2006. Int J Atheroscler 2006; 1:71-123.
10. Instituto Brasileiro de Geografia e Estatística (IBGE). Informações sobre censo populacional. Available at http://www.ibge.gov.br/censo/ [Accessed on 2 Jury 2004]
11. Maneia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, et al. 2007 Guidelines for the management of arterial hypertension. The task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2007; 28:1462-1536.
12. Krieger N, Williams DR, Moss NE. Measuring social class in U.S. public hearth research: concepts, methodologies, and guidelines. Annu Rev Publ Health 1997; 18:341-378. (Pubitemid 27194075)
13. Moreno FJA, Patencia MG, Peralta L, López AH, Castro FL Análisis de costes farmacológicos en el tratamiento de la hipertensión arterial. Aproximación a un estudio coste-efectividad. Available at http://db.doyma.es/cgi-bin/wdbcgi.exe/doyma/ mrevista.pubmed-full?inctrl= 05ZI0105&rev.... [Accessed 1 September 2005]
14. Piá AB, Loscos IA, Valero MG, Pérez JN, Giménez MH, Catalá MCT. Descripción de los costes y la efectividad de un programa de control de hipertensos em atención primaria. Available at http://db.doyma.es/cgi-bin/wdbcgi.exe/doyma/mrevista.pubmed-full?inctrl= 05ZI0105&rev. [Accessed 1 September 2005]
15. CR ConsultaRemédios [homepage na Internet]. Available at http://www.consultaremedios.com.br/. [Accessed 5 December 2007]
16. PAME - Associação de Assistência Plena em Saúde. Available at www.pame.com.br/consultas/consulta-medicamento.asp. [Accessed 10 May 2007]
17. Bishop YMM, Renberg SE, Holland PW. Discrete multivariate analysis: theory and practice. Cambridge: MIT Press; 1975.
18. Minitab Statistical Software, Minitab Inc. Available at http://www.minitab.com. [Accessed 1 October 2006]
19. Efrom B, Tibshirami RJ. An introduction to the Bootstrap. Monographs on statistic and applied probability, 57th ed. London: Chapman and Hall; 1993.
20. Schargrodsky H, Hemández-Hemnández R, Champagne BM, Silva H, Vinueza R, Ayçaguer LCS, et al. Carmela: assessment of cardiovascular risk in seven Latin American cities. Am J Med 2008; 121:58-65.
21. Wolf-Maier K, Cooper RS, Kramer H, Banegas JR, Giatnpaoli S, Joffres MR, et al. Hypertension treatment and control in five European countries, Canada, and the United States. Hypertension 2004; 43:10-17. (Pubitemid 38031904)
22. Wang Z, Wu Y, Zhao L, Li Y, Yang J, Zhou B, et al. Trends in prevalence, awareness, treatment and control of hypertension in the middle-aged population of China, 1992-1998. Hypertens Res 2004; 27:703-709.
23. Jo I, Ahn Y, Lee J, Shin KR, Lee HK, Shin C. Prevalence, awareness, treatment, control and risk factors of hypertension in Korea: the Ansan study. J Hypertens 2001; 19:1523-1532. (Pubitemid 32783768)
24. Orduñez-Garcia P, Munoz JLB, Pedraza D, Espinosa-Brito A, Silva LC, Cooper RS. Success in control of hypertension in a low-resource setting: The Cuban experience. J Hypertens 2006; 24:845-849. (Pubitemid 43670454)
25. Monroy OV, Peralta MR, Esqueda AI, Hernández GP, Grupo ENSA 2000, Attie F, et al. Hypertension in Mexico: The Health National Survey (ENSA) 2000. Arch Cardiol Mex 2002; 72:71-84.
26. Agyemang G, Bruijnzeels MA, Owusu-Dabo E. Factors associated with hypertension awareness, treatment, and control in Ghana, West Africa. J Hum Hypertens 2006; 20:67-71.
27. Steyn K. Hypertension in South Africa. In: Steyn K, Fourie J, editors. Chronic diseases of lifestyle in South Africa: 1995-2005. Canada: Athabasca University; 2006. pp. 80-96. (Pubitemid 26018056)
28. Borzecki AM, Glickman ME, Kader B, Berlowitz DR. The effect of age on hypertension control and management Am J Hypertens 2006; 19:520-527.
29. Uoyd-Jones DM, Evans JC, Levy D. Hypertension in adults across the age spectrum: current outcomes and control in the community. JAMA 2005; 294:466-472. (Pubitemid 41124179)
30. Antikainen RL, Moltchanov VA, Chukwuma C Sr, Kuulasmaa KA, MarquesVidal PM, Sans S, et al. Trends in the prevalence, awareness, treatment and control of hypertension: the WHO MONICA Project. Eur J Cardiovasc Prev Rehabil 2006; 13:13-29.
31. Bramlage P, Pittrow D, Wittchen H, Kirch W, Boehler S, Lehnert H, et al. Hypertension in overweight and obese primary care patients is highly prevalent and poorly controlled. Am J Hypertens 2004; 17:904-910. (Pubitemid 39366016)
32. Gaudemaris R, Lang T, Chatellier G, Larabi L, Lauwers-Cancès V, Maître A, et al. Socioeconomic inequalities in hypertension prevalence and care the IHPAF study- Hypertension 2002; 339:1119-1125. (Pubitemid 34620134)
33. Pereira M, Lunet N, Azevedo A, Barros H. Differences in prevalence, awareness, treatment and control of hypertension between developing and developed countries. J Hypertens 2009; 27:963-975.
34. Dias da Costa JS, Fuchs SC, Olinto MTA, Gigante DP, Menezes AMB, Macedo S, et al. Cost-effectiveness of hypertension treatment: a population-based study. Sao Paulo Med J 2002; 120:100-104. (Pubitemid 43051607)
35. Arredondo A. A review critique of incremental expenditures of hypertension treatment. Am J Hypertens 2006; 19:810-816.
36. Grilli R, Magrini N, Penna A, Mura G, Liberati A. Practice guidelines developed by specialty societies: the need for a critical appraisal. Lancet 2000; 355:103-106. (Pubitemid 30068554)
37. The Heart Outcomes Prevention Evaluation Study Investigators. Effecte of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Eng J Med 2000; 342:145-153.
38. Fox KM, EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators. Efficacy of Perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomized, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003; 362:782-788.
39. Fisher MA, Avorn J. Economic implications of evidence-based prescribing for hypertension - can better care cost less? JAMA 2004; 291:1850-1856. (Pubitemid 38509497)
40. Balu S, Thomas J III. Incremental expenditure of treating hypertension in the United States. Am J Hypertens 2006; 19:810-816. (Pubitemid 44107695)
41. Odell TW, Gregory MC. Cost of hypertension treatment J Gen Intern Med 1995; 10:686-688.
42. Ambrosioni E. Pharmacoeconomic challenges in disease management of hypertension. J Hypertens 2001; 19 (Suppl 3):S33-S40. (Pubitemid 33064349)
43. Calvo-Vargas CG, Carnilo JZP, Paez FG, Reyes SF. Changes in the coste of antihypertensive medications in a developing country. A study in México comparing 1990 and 1996. Am J Hypertens 1998; 11:487-493.